CD8A and neoplasm: To validate the ability of ex vivo-differentiated DCs to present tumor antigens and activate T cells, we pulsed FL/GM-DCs and GM/IL4-DCs with B16-OVA tumor lysates, then co-cultured those pulsed DCs with CD8+T cells isolated from OT-I transgenic mice (Figure 4h).